Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease

• Main Authors: Sumant Singh Chugh, Camille eMace, Lionel C Clement, Maria eDel Nogal Avila, Caroline eMarshall
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2014-02-01
• Series: Frontiers in Pharmacology
• Subjects: Diabetes Mellitus; Nephrotic Syndrome; Proteinuria; Sialic Acids; Therapeutics; focal and segmental glomerulosclerosis
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00023/full

Current drugs used to treat proteinuric disorders of the kidney have been borrowed from other branches of medicine, and are only partially effective. The discovery of a central, mechanistic role played by two different forms of the secreted glycoprotein Angiopoietin-like 4 (Angptl4) in human and experimental glomerular disease has opened new treatment avenues. Localized upregulation of a hyposialylated form (lacks sialic acid residues) of Angptl4 secreted by podocytes induces the cardinal morphological and clinical manifestations of human minimal change disease, and is also being increasingly recognized as a significant contributor towards proteinuria in experimental diabetic nephropathy. Oral treatment with low doses of N-acetyl-D-mannosamine (ManNAc), a naturally occurring precursor of sialic acid, improves sialylation of Angptl4 in vivo, and reduces proteinuria by over 40%. By contrast, a sialylated circulating form of Angptl4, mostly secreted from skeletal muscle, heart and adipose tissue in all major primary glomerular diseases, reduces proteinuria while also causing hypertriglyceridemia. Intravenous administration of recombinant human Angptl4 mutated to avoid hypertriglyceridemia and cleavage has remarkable efficacy in reducing proteinuria by as much as 65% for 2 weeks after a single low dose. Both interventions are mechanistically relevant, utilize naturally occurring pathways, and represent new generation therapeutic agents for chronic kidney disease related to glomerular disorders.